FOR IMMEDIATE RELEASE, Basildon, 9 November 2023
Pharmanovia, a global pharmaceutical company that repurposes and expands the lifecycle of novel and established medicines using value added approaches, is pleased to announce the appointment of James Burt as the new Chair of Medicines for Europe’s, Value Added Medicines (VAM) Sector Group.
The VAM Sector Group was established to work with industry, patients, healthcare professionals and payers, to create a sustainable market model that incentivises R&D on existing medicines and thus access to value added medicines in Europe. In his new role, James will work closely with the members of the VAM Group, Medicines for Europe staff, and other stakeholders, to represent its interests at a European level, to advocate for policies that support sustainable innovation and improve patient access to value added medicines.
Commenting, James Burt, CEO Pharmanovia and incoming Chair, Medicines for Europe’s VAM Sector Group, ”I’m delighted to take on the role as Chair of the VAM Sector Group and continue the important work of current Chair, Arun Narayan. I’ve been involved for a number of years as Vice Chair and passionately believe that there is so much untapped potential in value added medicines given the vast advances in new formulation and pharmaceutical technology.”
“VAMs are a cost-effective way of improving health outcomes across Europe, yet just 3% of the overall pharmaceutical market is currently supported by VAMs. Europe is behind other markets in its support for VAMs and so my priority as Chair will be to work with industry, regulators and healthcare system representatives to demonstrate the value of supportive pathways that encourage further investment and focus by the industry to realise the untapped potential of existing medicines.”
Commenting, Adrian van den Hoven, Director General, Medicines for Europe added: “I am happy to welcome James as Chair of the Value added medicines sector group at Medicines for Europe. James and his team have been dedicated for a number of years now to driving the policy framework for value added medicines. His engagement with our work helps us to understand company needs, so that any future regulatory pathway for this class of medicines ensures that the benefits get to patients and healthcare professionals quickly and equitably. James has a clear vision for the future of the sector and I am looking forward to working with him to achieve it.”
Notes to editors
For further information, please contact: Alison Dyson, Director of Communications, Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Their purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
They do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships.
In addition to expertise in life cycle management, Pharmanovia has a well-established presence in clinical development and the management of clinical trials. This extends beyond well-known brand names to encompass new-clinical entities that may have clinical trial commitments in the future.
Their diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
For more information about Pharmanovia, please visit www.pharmanovia.com
About Medicines for Europe
Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines for Europe, based on 5 important pillars: patients, quality, value, sustainability and partnership.